Evidence map›Paper›PMID 18816410›Full record

ArticleJournal of experimental & clinical cancer research : CR2008

Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant.

Xing-Chen Peng, Li Yang, Li-Ping Yang, Yong-Qiu Mao, Han-Shuo Yang, Ji-Yan Liu, Dong-Mei Zhang, Li-Juan Chen, Yu-Quan Wei

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Targeting PRPK Function Blocks Colon Cancer Metastasis.Molecular cancer therapeutics · 2018
    Article
  6. Novel CD44-downstream signaling pathways mediating breast tumor invasion.International journal of biological sciences · 2018
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xing-Chen PengState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Keyuan Road 4, Chengdu, Sichuan, PR China. pssabcd@sohu.com
Li Yang
Li-Ping Yang
Yong-Qiu Mao
Han-Shuo Yang
Ji-Yan Liu
Dong-Mei Zhang
Li-Juan Chen
Yu-Quan Wei
State Key Laboratory of BiotherapySichuan University · CN

Funding

Modifying Alcohol Approach Motivations with tDCS and Cognitive RetrainingR21AA021201 · NIAAA · THE MIND RESEARCH NETWORK · PI CLAUS, ERIC D · 2013 to 2014
$444k
NIAAA NIH HHS R21 AA021201
6 · The paper itself

Abstract

backgroundMetastasis in breast cancer is a vital concern in treatment because most women with primary breast cancer have micrometastases to distant sites at diagnosis. As a member of the inhibitor of apoptosis protein (IAP) family, survivin has been proposed as an attractive target for new anticancer interventions. In this study, we investigated the role of the plasmid encoding the phosphorylation-defective mouse survivin threonine 34-->alanine mutant (Msurvivin T34A plasmid) in suppressing both murine primary breast carcinomas and pulmonary metastases.

methodsIn vitro study, induction of apoptosis by Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol) was examined by PI staining fluorescence microscopy and flow cytometric analysis. The anti-tumor and anti-metastases activity of Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol) was evaluated in female BALB/c mice bearing 4T1 s.c. tumors. Mice were treated twice weekly with i.v. administration of Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol), PORF-9 null plasmid complexed with cationic liposome (DOTAP/Chol), 0.9% NaCl solution for 4 weeks. Tumor volume was observed. After sacrificed, tumor net weight was measured and Lung metastatic nodules of each group were counted. Assessment of apoptotic cells by TUNEL assay was conducted in tumor tissue. Microvessel density within tumor tissue was determined by CD31 immunohistochemistry. Alginate-encapsulated tumor cells test was conducted to evaluate the effect on angiogenesis. By experiment of cytotoxicity T lymphocytes, we test whether Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol) can induce specific cell immune response.

resultsAdministration of Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol) resulted in significant inhibition in the growth and metastases of 4T1 tumor model. These anti-tumor and anti-metastases responses were associated with triggering the apoptosis of tumor cells directly, inhibiting angiogenesis and inducing specific cellular immune response.

conclusionThe present findings suggest that the Msurvivin T34A plasmid complexed with cationic liposome may provide an effective approach to inhibit the growth and metastases of a highly metastatic mouse breast cancer model with minimal side effects.

Indexed as

Amino Acid SubstitutionGenetic TherapyAlanineAnimalsFatty Acids, MonounsaturatedFemaleGenetic VectorsGene Transfer TechniquesInhibitor of Apoptosis ProteinsLiposomesMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CMicroscopy, FluorescenceMicrotubule-Associated ProteinsNeoplasm Metastasis1,2-dioleoyloxy-3-(trimethylammonium)propaneAlanineBirc5 protein, mouseFatty Acids, MonounsaturatedInhibitor of Apoptosis ProteinsLiposomesMicrotubule-Associated ProteinsQuaternary Ammonium CompoundsRepressor ProteinsSurvivinThreonine

Identifiers

PMID18816410
PMCPMC2569909
OpenAlexW1984223966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.